Form 4: Ionis Pharma Exec's Equity Transactions & RSU Grants

Ionis Pharmaceuticals EVP Brian Birchler reported significant equity transactions, including RSU vesting, a tax-related stock sale, and new RSU and PRSU grants.

Summary

• Brian Birchler, EVP, Corporate and Development Operations at Ionis Pharmaceuticals Inc. (IONS), reported changes in his beneficial ownership of company securities.
• On January 15, 2026, 20,089 shares of common stock were acquired due to the vesting and release of Restricted Stock Unit (RSU) awards.
• Following the RSU vesting, 8,480 shares of common stock were sold on January 16, 2026, at a weighted average price of $75.11 per share, to cover required tax withholding obligations.
• The sale transactions occurred at prices ranging from $75.07 to $75.14 per share.
• A grant of 25,800 Performance Restricted Stock Units (PRSUs) was made on January 15, 2026, under the company's Amended and Restated 2011 Equity Incentive Plan.
• These PRSUs may vest at the end of a three-year performance period based on the Issuer's relative total shareholder return compared to a peer group, with the reported number representing the maximum (200% of target).
• An additional grant of 9,675 Restricted Stock Units (RSUs) was made on January 15, 2026, which will vest in four equal annual installments.
• After these transactions, Brian Birchler directly owns 60,435 shares of common stock, 79,138 PRSUs, and 50,801 RSUs.

Sentiment

Score: 5

Explanation: The filing reports routine insider transactions, including equity grants and a tax-related stock sale, which are standard components of executive compensation and do not inherently indicate positive or negative company performance.

Positives

• The grant of 25,800 Performance Restricted Stock Units (PRSUs) aligns executive incentives with shareholder returns over a three-year period.
• The grant of 9,675 Restricted Stock Units (RSUs) provides ongoing equity incentives and retention for the executive.

Negatives

• A sale of 8,480 shares of common stock, valued at approximately $637,072.80, reduces the executive's direct equity ownership, although it was for tax withholding purposes.

Risks

• The vesting of Performance Restricted Stock Units (PRSUs) is contingent on the company's relative total shareholder return compared to a peer group, meaning the actual number of shares received could range from zero to the maximum reported amount (25,800 units).
• The specific terms of the 9,675 RSU grant indicate an expiration date of January 15, 2027, while also stating they vest in four equal annual installments, which could imply a shorter or more complex vesting schedule than typical.

Future Outlook

The grant of Performance Restricted Stock Units (PRSUs) indicates a future focus on achieving strong relative total shareholder return over a three-year period, aligning executive compensation with long-term company performance.

Industry Context

This Form 4 filing details routine insider equity transactions, which are common in the biotechnology and pharmaceutical industry as part of executive compensation and retention strategies. The use of performance-based equity awards like PRSUs is a standard practice to align management incentives with shareholder value creation.

Corporate Governance

Stakeholder Impact

• Shareholders: The equity grants, particularly the performance-based units, aim to align executive interests with shareholder value creation, potentially benefiting long-term shareholders if performance targets are met.
• Employees: The compensation structure for executives, as evidenced by these grants, reflects the company's overall approach to incentivizing key personnel.

Next Steps

• The 25,800 Performance Restricted Stock Units will undergo a three-year performance period, with vesting contingent on the company's relative total shareholder return.
• The 9,675 Restricted Stock Units will vest in four equal annual installments.

Key Dates

Keywords

Ionis Pharmaceuticals, IONS, Form 4, Insider Transaction, Restricted Stock Units, Performance Restricted Stock Units, Executive Compensation, Equity Incentive Plan, Stock Sale, Tax Withholding